RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Public ClinicalTrials.gov record NCT01217411. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative
Study identification
- NCT ID
- NCT01217411
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 5 participants
Conditions and interventions
Conditions
- Adult Solid Neoplasm
- Extensive Stage Lung Small Cell Carcinoma
- HER2/Neu Negative
- HER2/Neu Positive
- Male Breast Carcinoma
- Metastatic Malignant Neoplasm in the Brain
- Recurrent Breast Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent Lung Small Cell Carcinoma
- Recurrent Melanoma
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
- Cognitive Assessment Procedure
- Gamma-Secretase Inhibitor RO4929097 Drug
- Laboratory Biomarker Analysis Other
- Stereotactic Radiosurgery Radiation
- Whole-Brain Radiotherapy Radiation
Procedure · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2010
- Primary completion
- Nov 29, 2011
- Completion
- Nov 29, 2011
- Last update posted
- Nov 18, 2024
2010 – 2011
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01217411, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01217411 live on ClinicalTrials.gov.